---
title: "Semiconductor M&A Surge and Leadership Shakeup Define Tech Sector's Turbulent September"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300408894.md"
description: "Skyworks' $22 billion Qorvo acquisition advances amid record RF breakthroughs, while executive exits at Tungray and sector-wide valuation pressures test resilience. Biotech firms race toward clinical milestones as semiconductor equipment demand shows tentative recovery."
datetime: "2026-09-29T09:14:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300408894.md)
  - [en](https://longbridge.com/en/news/300408894.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300408894.md)
generator: "portal-rs"
---

# Semiconductor M&A Surge and Leadership Shakeup Define Tech Sector's Turbulent September

The semiconductor sector faced unprecedented transformation in September as Skyworks Solutions moved closer to finalizing its $22 billion acquisition of Qorvo (QRVO.US). With 91.68% of 2029-dated notes tendered, the deal's completion now hinges on Chinese regulatory approval. Simultaneously, Qorvo achieved a 400% power density leap in DARPA-funded GaN transistor development, reinforcing its strategic value.

Axcelis Technologies (ACLS.US) signaled confidence in semiconductor equipment demand through its participation in September's ICSCRM conference, where CEO Russell Low highlighted the company's pivotal role in silicon carbide manufacturing. The firm's Q2 revenue grew 8.15% sequentially, contrasting with broader market volatility.

Leadership turbulence emerged as a sector-wide theme. Tungray Technologies (TRSG.US) saw abrupt CEO transition when Wanjun Yao resigned, succeeded by longtime executive Liling Du. FinVolution Group (FINV.US) faced intensified pressure as Chinese consumer credit platforms grappled with regulatory headwinds and Weiss Ratings' sell recommendation.

Biotech firms navigated critical junctures: Aclaris Therapeutics (ACRS.US) maintained 'strong buy' ratings despite revenue declines, while Quantum-Si (QSI.US) pushed back product launches but showcased promising proteomics data at World HUPO 2026. MoonLake Immunotherapeutics (MLTX.US) remained dependent on Phase III trial outcomes to justify its billion-dollar valuation.

AmpliTech Group (AMPG.US) reported 50.86% sequential revenue growth but warned of near-term margin pressures from 5G infrastructure investments. CCML.US and similar ETF vehicles remained largely dormant amid the sector's realignment.

### Related Stocks

- [FINV.US](https://longbridge.com/en/quote/FINV.US.md)
- [QRVO.US](https://longbridge.com/en/quote/QRVO.US.md)
- [CCML.US](https://longbridge.com/en/quote/CCML.US.md)
- [ACLS.US](https://longbridge.com/en/quote/ACLS.US.md)
- [TRSG.US](https://longbridge.com/en/quote/TRSG.US.md)
- [MLTX.US](https://longbridge.com/en/quote/MLTX.US.md)
- [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md)
- [AMPG.US](https://longbridge.com/en/quote/AMPG.US.md)
- [QSI.US](https://longbridge.com/en/quote/QSI.US.md)

## Related News & Research

- [Axcelis, Veeco Now Expect Merger to Close by End of Q1 2027](https://longbridge.com/en/news/303960342.md)
- [Aclaris Therapeutics, Inc. enters underwriting agreement for offering of 7,785,714 shares of common stock and 6,500,000 pre-funded warrants](https://longbridge.com/en/news/303325678.md)
- [Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug](https://longbridge.com/en/news/303272865.md)
- [ACRS: ATI-052 showed rapid AD and asthma activity; Phase 2b development will prioritize EoE](https://longbridge.com/en/news/303219733.md)
- [Aclaris Reports Positive Phase 1b Results for ATI-052 in Atopic Dermatitis, Asthma](https://longbridge.com/en/news/303206898.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**